NCT01451359

Brief Summary

Because an endobronchial valve is a one-way inspiratory airway blocker, it is hypothesized that it could be also used for controlling persistent air leaks while maintaining the drainage of secretions. The U.S. Food and Drug Administration approved in October 2008 the Spiration valve system designed to control air leaks in the lung that persist after lung surgery. This prospective observational study aims to evaluate the efficacy and safety of Spiration endobronchial valves in a prospective series of consecutive patients with a prolonged persistent air leak after anatomic surgical resection for cancer.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Oct 2011

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2011

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

October 4, 2011

Completed
9 days until next milestone

First Posted

Study publicly available on registry

October 13, 2011

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2013

Completed
Last Updated

October 10, 2013

Status Verified

October 1, 2011

Enrollment Period

2 years

First QC Date

October 4, 2011

Last Update Submit

October 8, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • clinical efficacy

    Clinical efficacy on air leak cessation allowing drain(s) removal.

    One month

Secondary Outcomes (1)

  • Safety

    One month

Study Arms (1)

endobronchial valve

EXPERIMENTAL

The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.

Device: EndoBronchial Valve

Interventions

The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.

Also known as: Spiration IBV™ valve system
endobronchial valve

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Prolonged (≥10 days postoperative) persistent air leak refractory to conventional treatments (such as prolonged drainage and/or chemical pleurodesis).
  • Anatomical lung resection such as segmentectomy, (bi)lobectomy or sleeve lobectomy.
  • Air leak after antero/posterolateral thoracotomy or video-assisted thoracoscopy (VATS).
  • Type of air leak : expiratory.
  • Size of air leak : any.

You may not qualify if:

  • Prolonged air leak \<10 days postoperative.
  • Pneumonectomy or none-anatomical lung resection.
  • Lung resection for another indication than cancer.
  • Previous reintervention or previous Heimlich valve for this air leak.
  • Empyema

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospitals Leuven

Leuven, Belgium

Location

Related Publications (1)

  • Dooms CA, Decaluwe H, Yserbyt J, De Leyn P, Van Raemdonck D, Ninane V. Bronchial valve treatment for pulmonary air leak after anatomical lung resection for cancer. Eur Respir J. 2014 Apr;43(4):1142-8. doi: 10.1183/09031936.00117613. Epub 2013 Nov 14.

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract NeoplasmsThoracic NeoplasmsNeoplasms by SiteNeoplasmsLung DiseasesRespiratory Tract Diseases

Study Officials

  • Chrtistophe Dooms, MD, PhD

    Universitaire Ziekenhuizen KU Leuven

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 4, 2011

First Posted

October 13, 2011

Study Start

October 1, 2011

Primary Completion

October 1, 2013

Study Completion

October 1, 2013

Last Updated

October 10, 2013

Record last verified: 2011-10

Locations